Cover Image
市場調查報告書

到前列腺癌症的全球市場 (2021年):患病人數的的增加市場成長促進

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth

出版商 GBI Research 商品編碼 347557
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
到前列腺癌症的全球市場 (2021年):患病人數的的增加市場成長促進 Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth
出版日期: 2015年11月01日 內容資訊: 英文 164 Pages
簡介

前列腺癌症是高齡者常見的疾病,60%的患者為65歲以上的男性。其病期進行緩慢,因人而異,但近年來由於檢查技術的進步,大部分都在早期階段便已發現。主要治療方法有手術或放射治療,但化療由於抗性的問題,只限Docetaxel。近來Zytiga和Xtandi通過核可,治療選擇正在重大的改變。全球前列腺癌症治療藥市場預測將從2014年的76億美元,成長到2021年的136億美元,以9.5%的年複合成長率(CAGR) 成長。

本報告提供全球前列腺癌症 (PC) 治療藥的市場相關分析,提供您疾病概要,及主要已上市/開發中產品的概要,臨床實驗的進展,全球主要國家的市場趨勢預測,近來的資本交易·產業聯盟的動向等調查評估。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 症狀和風險因素
  • 病因·病理生理學
  • 診斷方法
    • 數位式直腸婦科檢查
    • 影像診斷
    • 切片檢查
    • 腫瘤標記(癌症篩檢)
  • 疾病的分期與風險評估
  • 治療的演算法
    • 局部/局部惡化前列腺癌症
    • 荷爾蒙敏感度·轉移性前列腺癌症
    • 轉移性·閹割抗性前列腺癌
    • 熱圖:已上市產品概要

第3章 已上市產品

  • 荷爾蒙療法
    • 第1代
    • 第2代
  • 化療用藥物
    • Taxotere (Docetaxel ):Sanofi
    • Jevtana (cabazitaxel):Sanofi
  • 治療用疫苗
    • Provenge (sipuleucel-t):Dendreon
  • 骨轉移的治療
    • Xofigo (鐳223):Bayer/Algeta
    • Xgeva (Denosumab):Amgen
    • Zometa (唑來膦酸):Novartis

第4章 開發中產品的開發

  • 開發平台:各相位·目標分子別
  • 開發中產品的作用機制

第5章 臨床實驗

  • 臨床實驗的失敗率
  • 臨床實驗的持續期間
    • 臨床實驗的規模
  • 有潛力的開發平台分子
    • 局部疾病
    • mCRPC (閹割抗性前列腺癌):第一選擇
    • mCRPC:第二選擇

第6章 市場預測

  • 全球市場
    • 治療的利用模式
    • 市場規模
  • 北美市場
    • 美國
    • 加拿大
  • 歐洲主要5個國家
    • 治療上的利用模式
    • 年度治療費用
    • 市場規模
  • 日本
    • 治療上的利用模式
    • 年度治療費用
    • 市場規模

第7章 市場促進·阻礙因素

  • 推動市場要素
    • 末期患者治療主要的未滿足需求
    • 全球各國的人口高齡化,導致前列腺癌症患者的增加
    • Zytiga和Xtandi的利用擴大
    • 多數前列腺癌症產品的認證
    • 多數開發中產品
  • 市場阻礙因素
    • 近期/未來的專利到期
    • 隨著高價格,部分新藥物的利用受限

第8章 策略性的產業聯盟的動向

  • 共同開發 (全7件)
  • 許可證交易 (全5件)

第9章 附錄

  • 所有開發平台藥物:各Phase (藥物研發∼第III期)
  • 市場預測 (到2021年,全球·主要8個國家)
  • 參考文獻
  • 簡稱
  • 分析方法
  • 諮詢方式
  • 免責聲明

圖表一覽

目錄
Product Code: GBIHC373MR

Executive Summary

Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%). As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care. However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

The current late-stage drugs in development for PC address this clinical need, however, results so far have been mixed, with none demonstrating clinically transformative efficacy of safety. As a result, the growth in PC prevalence as a result of a global aging population is expected to be the key driver of this market throughout the forecast period.

Scope

Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.

What factors are driving the market growth?

How can the factors limiting growth be overcome in the future?

The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.

What other gaps in the market are being addressed by the current pipeline dynamics?

The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.

What are the dynamics of the remaining 50% of the pipeline?

How does this reflect the need for novel targeted therapies?

There has been a significant shift away from hormonal therapies. Key mechanisms of action across the pipeline include cancer immunotherapies against PSMA, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.

What is the scientific rationale behind these targets?

How successful have drugs against these targets been? How successful are they expected to be in the future?

Several drugs are expected to be approved during the forecast period: ProstAtak, ODM201, ARN-509, and Tookad. However, their sales are expected to be limited by high costs and a lack of comparative trials.

Where will these novel therapies fit into the current treatment algorithm for PC?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.
  • Visualize the composition of the PC market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.
  • Analyze the PC pipeline and stratify by stage of development, molecule type, and molecular target.
  • Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.
  • Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the AML market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.
  • Identify commercial opportunities in the PC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms and Risk Factors
  • 2.3. Etiology and Pathophysiology
  • 2.4. Diagnosis
    • 2.4.1. Digital Rectal Examination
    • 2.4.2. Imaging
    • 2.4.3. Biopsy
    • 2.4.4. Tumor Markers
  • 2.5. Disease Staging and Risk Assessment
  • 2.6. Treatment Algorithm
    • 2.6.1. Localized or Locally Advanced Prostate Cancer
    • 2.6.2. Hormone Sensitive Metastatic Prostate Cancer
    • 2.6.3. Metastatic Castration Resistant Prostate Cancer
    • 2.6.4. Heat Map - Marketed Products Overview

3. Marketed Products

  • 3.1. Hormonal Therapies
    • 3.1.1. First Generation
    • 3.1.2. Second Generation
  • 3.2. Chemotherapy Agents
    • 3.2.1. Taxotere (docetaxel) - Sanofi
    • 3.2.2. Jevtana (cabazitaxel) - Sanofi
  • 3.3. Therapeutic Vaccines
    • 3.3.1. Provenge (sipuleucel-t) - Dendreon
  • 3.4. Bone Metastasis Treatments
    • 3.4.1. Xofigo (radium 223) - Bayer/Algeta
    • 3.4.2. Xgeva (denosumab) - Amgen
    • 3.4.3. Zometa (zoledronic acid) - Novartis

4. Pipeline Product Developments

  • 4.1. Developmental Pipeline by Phase and Molecular Target
  • 4.2. Mechanisms of Action in the Pipeline

5. Clinical Trials

  • 5.1. Clinical Trial Failure Rate
  • 5.2. Clinical Trial Duration
    • 5.2.1. Clinical Trial Size
  • 5.3. Promising Pipeline Molecules
    • 5.3.1. Localized Disease
    • 5.3.2. mCRPC - First Line
    • 5.3.3. mCRPC - Second Line

6. Market Forecasts

  • 6.1. Global
    • 6.1.1. Treatment Usage Patterns
    • 6.1.2. Market Size
  • 6.2. North America
    • 6.2.1. US
    • 6.2.2. Canada
  • 6.3. Top Five European Markets
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. Japan
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size

7. Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Major Unmet Treatment Needs of Late-Stage PC Patients
    • 7.1.2. Increasing Incidence of PC Driven by Global Aging of Population
    • 7.1.3. Continued Uptake of Zytiga and Xtandi
    • 7.1.4. Approval of Numerous Premium Products in PC Market
    • 7.1.5. High Number of Pipeline Drugs
  • 7.2. Market Barriers
    • 7.2.1. Recent and Future Patent Expiries
    • 7.2.2. Uptake Limited by Premium Price of Several Novel Therapies

8. Strategic Consolidation

  • 8.1. Co-development Deals
    • 8.1.1. Pfizer Enters into Co-Development Agreement with Merck
    • 8.1.2. Immatics Enters into R&D Agreement with Roche for Cancer Vaccine
    • 8.1.3. Merck & Co Enters into Agreement with ARIAD Pharma
    • 8.1.4. Medivation Enters into Co-Development Agreement with Astellas Pharma
    • 8.1.5. Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products
    • 8.1.6. Bayer Schering Enters into Co-Development Agreement with Micromet
    • 8.1.7. Takeda Pharma Enters into Agreement with Cell Genesys
  • 8.2. Licensing Deals
    • 8.2.1. Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib
    • 8.2.2. Algeta Enters into Licensing Agreement with Bayer for Alpharadin
    • 8.2.3. Sanofi-Aventis Enters into Licensing Agreement with Oxford BioMedica
    • 8.2.4. Ascenta Therapeutics Enters into Licensing Agreement with Sanofi
    • 8.2.5. Aduro Biotech Enters into Exclusive Licensing Agreement with Janssen Biotech

9. Appendix

  • 9.1. All Pipeline Drugs by Phase
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. IND/CTA-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
  • 9.2. Market Forecasts to 2021
    • 9.2.1. Global
    • 9.2.2. US
    • 9.2.3. Canada
    • 9.2.4. UK
    • 9.2.5. France
    • 9.2.6. Germany
    • 9.2.7. Italy
    • 9.2.8. Spain
    • 9.2.9. Japan
  • 9.3. References
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Prostate Cancer Therapeutics, Commonly Mutated or Overexpressed Genes
  • Table 2: Prostate Cancer Therapeutics, Disease Stage Classification
  • Table 3: Prostate Cancer Therapeutics, Risk Classification for Localized Cancer, D'Amico System
  • Table 4: Prostate Cancer Therapeutics, Common Definitions of High-Risk Prostate Cancer
  • Table 5: Marketed GnRH Agonists and Their Routes of Administration for Prostate Cancer
  • Table 6: Prostate Cancer Therapeutics, Top Five European Markets, Forecast Growth in Prevalence and Treatment Populations, 2014-2021
  • Table 7: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014-2021
  • Table 8: Prostate Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2014-2021
  • Table 9: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Discovery, 2015
  • Table 10: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Preclinical, 2015
  • Table 11: Prostate Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA-Filed, 2015
  • Table 12: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2015
  • Table 13: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2015
  • Table 14: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2015
  • Table 15: Prostate Cancer Market, Global, Market Forecasts, 2014-2021
  • Table 16: Prostate Cancer Market, US, Market Forecasts, 2014-2021
  • Table 17: Prostate Cancer Market, Canada, Market Forecasts, 2014-2021
  • Table 18: Prostate Cancer Market, The UK, Market Forecasts, 2014-2021
  • Table 19: Prostate Cancer Market, France, Market Forecasts, 2014-2021
  • Table 20: Prostate Cancer Market, Germany, Market Forecasts, 2014-2021
  • Table 21: Prostate Cancer Market, Italy, Market Forecasts, 2014-2021
  • Table 22: Prostate Cancer Market, Spain, Market Forecasts, 2014-2021
  • Table 23: Prostate Cancer Market, Japan, Market Forecasts, 2014-2021

List of Figures

  • Figure 1: Prostate Cancer Therapeutics, Treatment, Stages I and II
  • Figure 2: Prostate Cancer Therapeutics, Treatment, Stage III
  • Figure 3: Prostate Cancer Therapeutics, Treatment, Stage IV
  • Figure 4: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Hormone Sensitive Disease
  • Figure 5: Prostate Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Hormone Sensitive Disease
  • Figure 6: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, First-line Treatment mCRPC
  • Figure 7: Prostate Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, First-line Treatment mCRPC
  • Figure 8: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Second-line Treatment mCRPC
  • Figure 9: Prostate Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Second-line Treatment mCRPC
  • Figure 10: Prostate Cancer Therapeutics, Global, Overview of Pipeline Products
  • Figure 11: Prostate Cancer Therapeutics, Global, Mechanisms of Action
  • Figure 12: Prostate Cancer Therapeutics, Global, Mechanisms of Action
  • Figure 13: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2006-2015
  • Figure 14: Market Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015
  • Figure 15: Prostate Cancer Therapeutics, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2006-2015
  • Figure 16: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2015
  • Figure 17: Prostate Cancer Therapeutics, Global, Clinical Trial Duration by Mechanism of Action (months), 2006-2015
  • Figure 18: Prostate Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2015
  • Figure 19: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Product by Mechanism of Action (participants), 2006-2015
  • Figure 20: Prostate Cancer Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2015
  • Figure 21: Prostate Cancer Therapeutics, Global, Clinical Trial Size of Products by Mechanism of Action (participants), 2006-2015
  • Figure 22: Prostate Cancer Therapeutics, Global, Tookad Revenue Forecast ($m), 2018-2021
  • Figure 23: Prostate Cancer Therapeutics, Global, ProstAtak Revenue Forecast ($m), 2019-2021
  • Figure 24: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline Products, Localized Disease
  • Figure 25: Prostate Cancer Therapeutics, Safety Results for Key Parameters - Pipeline Products, Localized Disease
  • Figure 26: Prostate Cancer Therapeutics, Global, ODM-201 Forecast Revenue ($m), 2018-2021
  • Figure 27: Prostate Cancer Therapeutics, Global, Prostvac Revenue Forecast ($m), 2017-2021
  • Figure 28: Prostate Cancer Therapeutics, Global, ARN-509 Revenue Forecast ($m), 2020-2021
  • Figure 29: Prostate Cancer Therapeutics, Global, Custirsen Sodium Revenue Forecast ($m), 2017-2021
  • Figure 30: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed (Highlighted in Blue) and Pipeline Products, mCRPC - First Line
  • Figure 31: Prostate Cancer Therapeutics, Safety Results for Key Parameters - Marketed (Highlighted in Blue) and Pipeline Products, mCRPC - First Line
  • Figure 32: Prostate Cancer Therapeutics, Global, DCVAC Revenue Forecast ($m), 2019-2021
  • Figure 33: Prostate Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed (Highlighted in Blue) and Pipeline Products, mCRPC - Second Line
  • Figure 34: Prostate Cancer Therapeutics, Global, Treatment Usage Patterns ('000), 2014-2021
  • Figure 35: Prostate Cancer Therapeutics, Global, Market Size ($bn), 2014-2021
  • Figure 36: Prostate Cancer Therapeutics, US, Treatment Usage Patterns ('000) and Annual Cost of Therapy ($), 2014-2021
  • Figure 37: Prostate Cancer Therapeutics, US, Market Revenue ($m), 2014-2021
  • Figure 38: Prostate Cancer Therapeutics, Canada, Treatment Usage Patterns and ACoT ('000; $), 2014-2021
  • Figure 39: Prostate Cancer Therapeutics, Canada, Market Revenue ($m), 2014-2021
  • Figure 40: Prostate Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns ('000), 2014-2021
  • Figure 41: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014-2021
  • Figure 42: Prostate Cancer Therapeutics, Top Five European Markets, Market Revenue ($m), 2014-2021
  • Figure 43: Prostate Cancer Therapeutics, Japan, Treatment Usage Patterns and Annual Cost of Therapy ('000; $), 2014-2021
  • Figure 44: Prostate Cancer Therapeutics, Japan, Market Revenue ($m), 2014-2021
  • Figure 45: Prostate Cancer Therapeutics, Global, Co-Development Deals by Region, Value and Year, 2006-2014
  • Figure 46: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006-2014
  • Figure 47: Prostate Cancer Therapeutics, Global, Co-Development Deals by Molecule Type, 2006-2014
  • Figure 48: Prostate Cancer Therapeutics, Global, Licensing Deals by Value and Year, 2006-2014
  • Figure 49: Prostate Cancer Therapeutics, Global, Licensing Deals by Phase and Molecule Type, 2006-2014
  • Figure 50: Prostate Cancer Therapeutics, Global, Licensing Deals by Mechanism of Action, 2006-2014
Back to Top